STAT+: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
Doctors have been eagerly waiting for data on Guardant Health’s new blood-based colorectal cancer screening test, the Shield test. The hope
